01/09/2026
Known as the "silent pandemic," the threat of antimicrobial resistance (AMR) continues to surge. đź¦
For Associate Professor Dr. Mark Mitton-Fry, this rapidly growing phenomenon has been the focus of his work for the past 20 years.
His research team at the college is devoted to discovering Novel Bacterial Topoisomerase Inhibitor (NBTI) compounds to treat resistant infections.
“I’m motivated by the scale of this problem, and I’m truly fascinated by the resistant pathogens we’re focusing on.”
Read more about Dr. Mitton-Fry and how his research aims to counter AMR in the latest issue of The Script magazine.
Playing the long game: How the Mitton-Fry Lab is advancing treatment of multidrug-resistant infections December 8, 2025 This article was published in The Script Magazine – Autumn 2025. Antimicrobial resistance (AMR) is a major cause of mortality around the world. AMR makes fighting infections incr...